BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Leo Cancer Care and Sumitomo Heavy Industries Partner to Launch Upright Proton Therapy Solution

Leo Cancer Care, a leader in innovative cancer care solutions, and Sumitomo Heavy Industries, a global pioneer in medical technology, have announced a stra...

September 29, 2025 | News

Hengrui Pharma Grants Glenmark Exclusive Global Licence for HER2-Targeted ADC Trastuzumab Rezetecan

Hengrui Pharma, a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced that it has entered ...

September 25, 2025 | News

Lunit and CellCarta Form Global Partnership to Advance AI-Powered Pathology in Clinical Trials

Lunit , a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, announced a strategic partnership with CellCarta, a globa...

September 25, 2025 | News

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Advance AI-Powered Genomic Testing in Breast and Prostate Cancer

SOPHiA GENETICS an AI technology company transforming precision medicine announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq:...

September 23, 2025 | News

Lunit and Agilent Forge Collaboration to Develop AI-Powered Companion Diagnostics

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabili...

September 23, 2025 | News

Sanofi and Regeneron Receive CHMP Recommendation for Dupixent in Chronic Spontaneous Urticaria in EU

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo ...

September 23, 2025 | News

DEBRA Research and Nonsense Therapeutics Launch ReadOn Therapeutics to Advance Treatments for Epidermolysis Bullosa

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis bullosa (EB...

September 23, 2025 | News

OGT secures FDA De Novo classification for CytoCell® KMT2A FISH probe as companion diagnostic to Syndax’s Revuforj®

OGT, a leading global provider of genomic diagnostic and research solutions, announced that the U.S. Food and Drug Administration (FDA) has granted th...

September 23, 2025 | News

JCR Pharmaceuticals Achieves Milestone with Alexion in Neurodegenerative Disease Collaboration

-JCR Pharmaceuticals Co., Ltd., a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved ...

September 22, 2025 | News

Henlius and Organon Secure EC Approvals for Denosumab Biosimilars BILDYOS® and BILPREVDA®

Shanghai Henlius Biotech, Inc., and Organon announced the European Commission (EC) has granted marketing authorization for BILDYOS® (de...

September 22, 2025 | News

Kexing Biopharm Completes FDA Type II DMF Registration for Stem Cell-Derived Exosomes

Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Ma...

September 18, 2025 | News

Johnson & Johnson’s Amivantamab–Lazertinib Combo Extends Survival Beyond Four Years in Asia NSCLC Cohort

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...

September 17, 2025 | News

Co-Diagnostics Signs Saudi MOU to Establish Joint Venture for PCR Manufacturing and Distribution in the Middle East

The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of th...

September 17, 2025 | News

Japan Approves Novocure’s Optune Lua for Concurrent Use with PD-1/PD-L1 Inhibitors in Advanced NSCLC

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...

September 17, 2025 | News

Stay Connected